Linaclotide - a secretagogue and antihyperalgesic agent - what next?

Area of Science:

• Gastroenterology
• Pharmacology
• Pain Research

Background:

• Linaclotide is an FDA-approved guanylate cyclase-C (GC-C) receptor agonist used for chronic constipation.
• Inflammation and stress can lead to visceral hypersensitivity, a common symptom in functional gastrointestinal disorders.

Purpose of the Study:

• To investigate the potential antihyperalgesic effects of linaclotide in rat models of inflammation- and stress-induced hypersensitivity.
• To explore the role of GC-C receptors in mediating these effects.

Main Methods:

• Linaclotide was administered to rats with induced colitis, water avoidance stress, or restraint stress.
• Hyperalgesia was assessed, and the involvement of GC-C receptors was investigated in mice.
• Dose-effect relationships were analyzed.

Main Results:

• Linaclotide demonstrated antihyperalgesic effects in inflammation- and stress-induced hypersensitivity models in rats.
• These effects were partly mediated by GC-C receptors in mice.
• No effects were observed in non-sensitized (naïve) animals.
• Dose-effect relationships were complex and non-linear.

Conclusions:

• Linaclotide may possess therapeutic potential beyond chronic constipation, including the management of visceral hypersensitivity.
• GC-C receptors might play a broader role in regulating gastrointestinal sensitivity in disease states.
• Further investigation in humans and long-term animal models is warranted to confirm findings and elucidate mechanisms.